NCT06671236View on ClinicalTrials.gov

Clinical Study of Regulatory T Cells (Tregs) in the Treatment of Neurodegenerative Diseases

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 21, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
BIOLOGICAL

Autologous Human Polyclonal Regulatory T Cells Injection (NP001 Cell Injection)

Regulatory T cell therapy, intrathecal injection

Trial Locations (1)

450052

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

Sponsors
All Listed Sponsors
collaborator

The First Affiliated Hospital of Zhengzhou University

OTHER

lead

Novabio Therapeutics

INDUSTRY

NCT06671236 - Clinical Study of Regulatory T Cells (Tregs) in the Treatment of Neurodegenerative Diseases | Biotech Hunter | Biotech Hunter